Form 8-K - Current report:
SEC Accession No. 0001013762-24-002775
Filing Date
2024-07-30
Accepted
2024-07-30 17:26:23
Documents
15
Period of Report
2024-07-29
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0210280-8k_virpax.htm   iXBRL 8-K 42123
2 AMENDMENT TO THE VIRPAX PHARMACEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN TO INCR ea021028001ex10-1_virpax.htm EX-10.1 6757
3 AMENDMENT TO THE VIRPAX PHARMACEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN TO INCR ea021028001ex10-2_virpax.htm EX-10.2 7110
  Complete submission text file 0001013762-24-002775.txt   238625

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE vrpx-20240729.xsd EX-101.SCH 3027
5 XBRL LABEL FILE vrpx-20240729_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE vrpx-20240729_pre.xml EX-101.PRE 22367
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0210280-8k_virpax_htm.xml XML 3806
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

EIN.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 241158990
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)